About Precise Bio
Precise Bio is a Healthcare company based in Winston-salem (United States) founded in 2015 by Shay Soker, Aryeh Batt, and Anthony Atala. Developer of integrated 3D printing and tissue-engineering platform. It operates in the Healthcare and Technology sectors. Precise Bio has raised $12 million across 3 funding rounds from investors including ZEISS. The company has 6 employees. Its chief executive, as recorded, is Aryeh Batt. Precise Bio offers products and services including Precise Bio Platform and Ophthalmology Unit. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is PRECISE BIO, INC. Its competitors include CELLINK and Allevi; 1 of its 2 listed competitors has raised funding.
Company details
Precise Bio was founded in 2015 in Winston-Salem, United States. An integrated 3D printing and tissue-engineering platform is developed for the regenerative medicine sector. Repeatable bio-fabricated organs are produced from patients own cells, targeting cardiology, orthopedics, dermatology, and additional areas. The lead product, a 3D cardiac tissue patch, is implanted post-myocardial infarction to restore cardiac muscle viability and functionality.
- Headquarters Winston-salem, United States
- Employees 6
- Founders Shay Soker, Aryeh Batt, Anthony Atala
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website precise-bio.com
- Social LinkedIn
- Legal Name Precise Bio, Inc.
- Total Equity Funding$12M (USD)
in 3 rounds
- Latest Funding Round$12M (USD), Series B
Jan 2024
- Investors
- Employee Count6
Products & Services of Precise Bio
Precise Bio offers a comprehensive portfolio of products and services, including Precise Bio Platform and Ophthalmology Unit.
Integrated system for bio-fabricating tissues and organs using patient cells.
Dedicated unit for eye-related bio-fabrication and tissue engineering.
Funding Insights of Precise Bio
Precise Bio has successfully raised a total of $12M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12M
- Total Rounds 3
- Last Round Series B — $12M
- First Round $15.53M
(Feb 2022)
- Investors Count 1
All 3 funding rounds of Precise Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $12M | Series B | – | – | – |
| Jul 2022 | Seed | – | ZEISS | – | |
| Feb 2022 | $15.53M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Precise Bio
Precise Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ZEISS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of diversified optics for microscopic instruments, medical imaging systems and more | 1846 | zeiss.com | Oberkochen, Germany |
Investor details for Precise Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Precise Bio
13 people are tracked at Precise Bio (7 in leadership, 1 in board & advisors, 5 in team); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Shay Soker | Co-Founder & CSO | Leadership |
Aryeh Batt | Co-Founder & CEO | Leadership |
Anthony Atala | Co-Founder & CMO | Leadership |
Lior Rosenberg Belmaker | Head Of CMC | Leadership |
Amos Eitan | VP, R&D | Leadership |
Yishay Hayardeni | VP. Projects & System | Leadership |
Eyal Arieli | CFO & COO | Leadership |
Richard L. Lindstrom | Advisor | Board & advisors |
Daniela Gicovate | Administrative Manager | Team |
Tal Tenne | Administrative Manager | Team |
Hadass Reich (Ph.D, CMQ) | QA Manager | Team |
Menucha Nadav | Bioengineering Researcher | Team |
Maayan Malki | Bio-materials Research Team Leader | Team |
Complete people profiles for Precise Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Precise Bio
3 dated milestones of Precise Bio across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Precise Bio is founded.
- Funding First funding round of $15.5M.
- Funding Latest funding round, Series B, of $12.0M.
Competitors of Precise Bio
Precise Bio has 2 listed competitors in our database, 1 of them funded. They include CELLINK and Allevi.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellink.com | 2016 | Boston, United States | 65 | 3D bioprinters and bioinks are developed for research applications. | ||
| allevi3d.com | 2014 | Philadelphia, United States | $3.58M | Industrial-grade 3D bioprinters and bioprinting materials are manufactured. |
Detailed competitors of Precise Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Precise Bio
The website of Precise Bio (precise-bio.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 47.7% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Precise Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Precise Bio
Complete news archive for Precise Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precise Bio
Precise Bio was founded in 2015 and raised its 1st funding round 7 years after it was founded.
Precise Bio is headquartered in Winston-salem, United States. It is registered at Winston-salem, North Carolina, United States.
Aryeh Batt is the CEO of Precise Bio, as recorded in our data. They have also founded this company.
Precise Bio is a funded company, having raised a total of $12M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $15.53M, raised on Feb 2022.
Precise Bio has 6 employees.
Precise Bio was founded in 2015 in Winston-Salem, United States. An integrated 3D printing and tissue-engineering platform is developed for the regenerative medicine sector. Repeatable bio-fabricated organs are produced from patients own cells, targeting cardiology, orthopedics, dermatology, and additional areas. The lead product, a 3D cardiac tissue patch, is implanted post-myocardial infarction to restore cardiac muscle viability and functionality.
Precise Bio offers Precise Bio Platform and Ophthalmology Unit.
Precise Bio has 1 investor. Key investors include ZEISS.
Precise Bio operates through Precise Bio, Inc..